InnoCare Pharma Inc.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase I Study of ICP-332 in Healthy Subjects (NCT06530966) | InnoCare Pharma Inc. | 2024-07-23 |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL (NCT06363994) | InnoCare Pharma Inc. | 2024-05-29 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies (NCT06351527) | InnoCare Pharma Inc. | 2024-04-23 |
| Evaluating Different Doses of Orelabrutinib in MCL (NCT05978739) | InnoCare Pharma Inc. | 2023-08-18 |
| Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors (NCT05537987) | InnoCare Pharma Inc. | 2021-07-30 |
Track InnoCare Pharma Inc. automatically
Every clearance here is in the API, with alerts when new ones post.